Encore Vision
Novartis presents positive results from two phase 3 trials for relapsing MS
Remibrutinib reduced relapse rates and improved disease progression rates
Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
Novartis announces trial results for remibrutinib in relapsing multiple sclerosis
MS affects nearly three million people worldwide and has three main types
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Cases of skin cancer set to reach 263,000 in 2035 according to new report
The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates
Novartis breaks ground on US radioligand therapy site
The construction is part of the company’s investment in US research and manufacturing
Lilly commits additional $4.5bn for US manufacturing sites
The company has also opened its first dedicated genetic medicine facility in Indiana in the US
Potential US-Iran peace deal to redraw market winners and losers
With a 10-day ceasefire between Israel and Lebanon in effect, oil prices are retreating from recent highs
Novartis to acquire Excellergy in deal worth up to $2bn
Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases
Scotland becomes first part of UK to screen all newborn babies for SMA
The screening is part of a two-year evaluation funded by the Scottish government and Novartis
Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment
The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study